The company’s R&D expenditure will come down to 7-7.5 percent of sales after the disinvestment in Glenmark Lifesciences. It was virtually double, at 14.2 percent of sales, in FY 17-18
Apollo’s mainstay hospitals business saw 13% growth. The other segments, Apollo Health and Lifestyle Ltd (AHLL) and Apollo HealthCo continued to show improvement.
Cipla stock price jumped more than 3 per cent on Friday after reports that Blackstone is in talks to buy out the promoter stake in the company.Last week, Ciplahad clarified that the company is not aware of any event that requires disclosure .